SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Microcapcorner

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: phonepo267/15/2008 8:58:17 AM
   of 724
 
Symbol: MEDP.PK

Current Price .013

Tradable float-11m

Medspas Reports Positive Clinical Test Results on the Versatile Penzyme Healing Enzyme
Monday July 14, 5:18 pm ET

ATLANTA, GA--(MARKET WIRE)--Jul 14, 2008 -- Medspas of America Inc. (Other OTC:MEDP.PK - News), www.medspasofamerica.com. Two important clinical tests and nine additional clinical observations have been completed on Penzyme, leading to extremely favorable results and excellent news for Medspas. Penzim is the active and main ingredient in its Natural Renu anti-aging cream and gel.

Penzyme is truly an amazing product which utilizes purified enzymes that have a deep-healing effect on the body when applied. The versatility for uses of Penzyme provides Medspas with a giant global platform to market and distribute Natural Renu. Penzyme was found to accelerate the healing time for inflammation and pain for osteoarthritis, tendonitis, tendosynovitis, fibromyalgia, muscle aches, trigger points, rheumatoid arthritis, lymphagitis, varicose veins, phlebitis and also helps to reduce pain of UV Radiation burns and wound-healing of pressure sores.

Cosmetically, Penzyme has been proven to provide relief of psoriasis, acne, boils, pimples, eczema and dermatitis, including nourishing, moisturizing, smoothing and rejuvenating the skin. "We believe we've stumbled onto a miracle cream and are extremely confident in the worldwide growth of Penzyme and feel fortunate that it collides directly with Medspa's success," stated CEO Paul Smith.

The beneficial properties of Penzyme have also been confirmed in laboratory research, partner funded clinical studies, and direct feedback from consumers. Clinical studies and observations of over 400 participants have been completed for the use of Penzyme in medical and cosmetic applications, which lends a great deal of credibility to its authenticity. "We are on a mission to get our Natural Renu product into every medicine cabinet across the globe," stated CEO Paul Smith.

Zymetech owns the worldwide patents for an active ingredient called Penzyme, which is sold under the trademark of Penzim, and is derived from enzymes produced by fish, particularly cod in the North Atlantic. The Company has signed a supply licensing agreement with Zymetech, Inc., www.zymetech.com, for the use of Penzim in its anti-aging product lines.

About Natural Renu

The company has established a new division to penetrate the $5.4 billion cosmeceutical industry under the brand name Natural Renu. The company's new initiative is a line of cosmeceutical products focusing on the anti-aging and skin healthcare markets. The company sales efforts are focused primarily through two marketing channels. The first and primary sales channel is Internet Retailing. The second target audience is to exclusive Plastic Surgeons and Dermatology practices, Day spas, Resorts and Medspas around the world.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext